Diagnostic accuracy of the Copenhagen Index in ovarian malignancy: A meta-analysis

• Published in: PloS one Vol. 18; no. 6; p. e0286650
• Main Authors: Liu, Huiling, Ma, Shouye, Chen, Xiaohong, Wu, Huifang, Wang, Rongrong, Du, Mengmeng, Nie, Xiazi
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 14.06.2023; Public Library of Science (PLoS)
• Subjects: Accuracy; Advertising agencies; Analysis; Bias; Biomarkers; Cancer; Care and treatment; Diagnosis; Diagnostic systems; Malignancy; Mathematical analysis; Medical diagnosis; Medical ethics; Medical prognosis; Medical research; Medical screening; Medicine and Health Sciences; Medicine, Experimental; Meta-analysis; Mortality; Ovarian cancer; Ovarian carcinoma; Patient outcomes; People and Places; Physical Sciences; Research and Analysis Methods; Science Policy; Sensitivity; Sensitivity analysis; Software; Statistical analysis; Testing; Tumor antigens; Tumor markers; Tumors; Ultrasonic imaging; China; United States
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0286650

To assess the diagnostic value of the Copenhagen index for ovarian malignancy. PubMed, Web of Science, the Cochrane Library, Embase, CBM, CNKI, and WanFang databases were searched throughout June 2021. Statistical analyses were performed using Stata 12, Meta-DiSc, and RevMan 5.3. The pooled sensitivity, specificity, and diagnostic odds ratio were calculated, the summary receiver operating characteristic curve was drawn, and the area under the curve was calculated. Ten articles, including 11 studies with a total of 5266 patients, were included. The pooled sensitivity, specificity, and diagnostic odds ratio were 0.82 [95% CI (0.80-0.83)], 0.88 [95% CI (0.87-0.89)], and 57.31 [95% CI (32.84-100.02)], respectively. The area under the summary receiver operating characteristics curve and the Q index were 0.9545 and 0.8966, respectively. Our systematic review shows that the sensitivity and specificity of the Copenhagen index are high enough for it to be used in a clinical setting to provide accurate ovarian cancer diagnosis without considering menopausal status.